Isarna Therapeutics has exciting news to share at two upcoming conferences in Seattle, Washington. Prof. Marion R. Munk, the Chief Medical Officer of Isarna, will present updated clinical data from the Phase 2 BETTER study, focusing on the company’s lead program, ISTH0036, at the OIS Retina Innovation Summit on May 4th and the Association for Research in Vision and Ophthalmology (ARVO) Meeting on May 7th.
ISTH0036 is an innovative RNA-based antisense molecule that is designed to target and block the production of transforming growth factor-beta (TGF-β), which plays a significant role in fibrosis associated with ophthalmic pathology. The ongoing trial has demonstrated a favorable safety profile for ISTH0036, along with positive efficacy results in patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The data analysis conducted using RetinAI AG’s AI-powered Discovery platform revealed that ISTH0036 not only prevents fibrosis and epithelial-mesenchymal transition but also demonstrates a drying effect, distinguishing it from existing anti-angiogenic therapies that primarily target Vascular Endothelial Growth Factors (VEGF).
Dr. Rene Rückert, the Chief Operating Officer of Isarna Therapeutics, expressed the team’s enthusiasm in presenting the recent findings from the ongoing clinical study to experts within the ophthalmology community. He emphasized that the BETTER study, a Phase 2 parallel, open-label, two-segment clinical trial, is advancing well, examining its primary endpoint of reducing retinal fluid and central macular thickness while also assessing the improvement of visual acuity as a secondary endpoint. The trial includes both newly diagnosed patients and individuals who have previously received anti-VEGF treatments. Renowned experts at clinical trial centers in Austria and India are conducting the study in collaboration with Isarna’s expert advisory board.
Isarna Therapeutics, an organization with a deep understanding of antisense oligonucleotide design and RNA technology, is devoted to developing antisense therapies that target TGF-β signaling, a promising therapeutic area in human biology. The precise modulation of TGF-β pathways through antisense therapy has the potential to offer safer and more effective treatment options for various indications. Currently, Isarna is dedicated to the field of ophthalmology, with its lead compound, ISTH0036, undergoing Phase 2 clinical development for wet AMD and DME. In addition, Isarna has a portfolio of antisense compounds addressing multiple isoforms of TGF-β to treat fibrotic diseases and different forms of cancer.
For media inquiries, please contact Trophic Communications at [email protected] or call Gretchen Schweitzer or Desmond James at +49 151 678 59086.
Isarna Therapeutics is set to present updated Phase 2 clinical data at two prominent ophthalmology conferences. The company’s Chief Medical Officer, Prof. Marion R. Munk, will be sharing the latest clinical data from the Phase 2 BETTER study, with a focus on Isarna’s lead program, ISTH0036. This innovative RNA-based antisense molecule is designed to target and block the production of transforming growth factor-beta (TGF-β), a key player in ophthalmic pathology-related fibrosis.
The ongoing trial has shown a favorable safety profile for ISTH0036, along with positive efficacy results in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Notably, the data analysis conducted using RetinAI AG’s AI-powered Discovery platform revealed that ISTH0036 not only prevents fibrosis and epithelial-mesenchymal transition but also exhibits a drying effect, distinguishing it from existing anti-angiogenic therapies that primarily target Vascular Endothelial Growth Factors (VEGF).
The Chief Operating Officer of Isarna Therapeutics, Dr. Rene Rückert, expressed excitement in presenting these recent findings to experts in the ophthalmology community. The Phase 2 BETTER study is progressing well, examining the primary endpoint of reducing retinal fluid and central macular thickness, while also assessing visual acuity improvement as a secondary endpoint. The trial includes both newly diagnosed patients and individuals who have previously received anti-VEGF treatments, with renowned experts at clinical trial centers in Austria and India collaborating with Isarna’s expert advisory board.
Isarna Therapeutics, a company with expertise in antisense oligonucleotide design and RNA technology, is dedicated to developing antisense therapies targeting TGF-β signaling, an area with significant therapeutic promise. Precisely modulating TGF-β pathways through antisense therapy has the potential to offer safer and more effective treatment options for various indications. Isarna’s current focus is on ophthalmology, with ISTH0036 undergoing Phase 2 clinical development for wet AMD and DME. In addition, Isarna has a portfolio of antisense compounds addressing multiple isoforms of TGF-β to tackle fibrotic diseases and different forms of cancer.
As for the advantages of ISTH0036, the favorable safety profile and positive efficacy results suggest its potential as a safer and more effective treatment for wet AMD and DME compared to existing therapies. Furthermore, the drying effect observed differentiates it from anti-VEGF therapies, potentially offering an additional benefit in managing these conditions.
However, challenges and controversies associated with ISTH0036 and Isarna Therapeutics’ approach may include the need for further validation of clinical efficacy in larger patient populations and potential competition from other emerging therapies targeting TGF-β signaling.
For more information, media inquiries can be directed to Trophic Communications at [email protected] or by contacting Gretchen Schweitzer or Desmond James at +49 151 678 59086.